

174 Antipsychotics

REFERENCES

1. Richelson E: Receptor pharmacology of neuroleptics: relation to clinical effects. *J Clin Psychiatry* 60(suppl 10): 5, 1999.
2. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 27: 1159, 2003.
3. Cortese L, Pourcher-Bouchard E, Williams R: Assessment and management of anti-psychotic-induced adverse events. *Can J Psychiatry* 43 (suppl 1): 15S, 1998.
4. Pierre JM: Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. *Drug Saf* 28: 191, 2005.
5. Iqbal N, Lambert T, Masand P: Akathisia: problem of history or concern of today. *CNS Spectr* 12(9 suppl 14): 1, 2007.
6. Strawn JR, Keck PE, Caroff SN: Neuroleptic malignant syndrome. *Am J Psychiatry* 164: 870, 2007.
7. Caroff SN, Mann SC: Neuroleptic malignant syndrome. *Med Clin North Am* 77: 185, 1993.
8. Croarkin PE, Emslie GJ, Mayes T: Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. *J Clin Psychiatry* 69: 1157, 2008.
9. Levenson J: Neuroleptic malignant syndrome. *Am J Psychiatry* 142: 1137, 1985.
10. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision*. Washington DC, American Psychiatric Association, 2000, pp. 795-798.
11. Troller JN, Sachdev PS: Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. *Aust N Z J Psychiatry* 33: 650, 1999.
12. Ramaswamy K, Masand PS, Nasrallah HA: Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry* 18: 183, 2006.
13. Lipscombe LL, Lévesque L, Gruneir A, et al: Antipsychotic drugs and hyperglycemia in older patients with diabetes. *Arch Intern Med* 169: 1282, 2009.
14. Haddad PM, Sharma SG: Adverse effects of atypical antipsychotics: differential risk and clinical implications. *CNS Drugs* 21: 911, 2007.
15. Sedky K, Lippmann S: Psychotropic medications and leukopenia. *Curr Drug Targets* 7: 1191, 2006.
16. Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. *Hum Psychopharmacol* 23(suppl 1): 15, 2008.
17. Hedges D, Jeppson K, Whitehead P: Antipsychotic medication and seizures: a review. *Drugs Today (Barc)* 39: 551, 2003.
18. Zemrak WR, Kenna GA: Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. *Am J Health Syst Pharm* 65: 1029, 2008.
19. Cobough DJ, Erdman AR, Booze LL, et al: Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. *Clin Toxicol (Phila)* 45: 918, 2007.
20. Trenton A, Currier G, Zwemer F: Fatalities associated with therapeutic use and overdose of atypical antipsychotics. *CNS Drugs* 17: 307, 2003.
21. Tan HH, Hoppe J, Heard K: A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. *Am J Emerg Med* 27: 607, 2009.
22. Albertson TE, Dawson A, de Latorre F, et al: TOX-ACLS: toxicologic-oriented advanced life support. *Ann Emerg Med* 37(4 suppl): S78, 2001.

USEFUL WEB RESOURCES

American Association of Poison Control Centers—<http://www.aapcc.org/DNN/>
 American Academy of Clinical Toxicology—<http://www.clintox.org/index.cfm>
 European Association of Poisons Centres and Clinical Toxicologists—<http://www.eapct.org/>
 Asia Pacific Association of Medical Toxicology—<http://www.asiatox.org/>
 South Asian Clinical Toxicology Research Collaboration—<http://www.sactrc.org/>